# A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis

> **NCT00458146** · PHASE2 · COMPLETED · sponsor: **Merrimack Pharmaceuticals** · enrollment: 100 (estimated)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MM-093

## Key facts

- **NCT ID:** NCT00458146
- **Lead sponsor:** Merrimack Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-02
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2008-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00458146

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00458146, "A Phase 2 Study to Evaluate the Efficacy and Safety of 60mg of MM-093 in Patients With Active Rheumatoid Arthritis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00458146. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*